FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912319965> ?p ?o ?g. }

• W2912319965 endingPage "1789" @default.
• W2912319965 startingPage "1789" @default.
• W2912319965 abstract "Abstract Background : Anagrelide is a widely used therapeutic agent for patients with essential thrombocythemia. While other cytoreductive agents, such as hydroxyurea, influence multi-lineage blood cells, anagrelide exerts less effect on the white and red blood cell lineages. Although the clinical efficacy of anagrelide has been reported, the exact mechanism of action is unclear. Recently, immortalized megakaryocyte progenitor cell lines (imMKCLs) were established from human induced pluripotent stem (iPS) cells by the introduction of doxycycline-inducible lentiviral vectors harboring c-MYC, BMI1, and BCL-XL for the clinical application of artificially generated platelets. In this study, we aimed to elucidate the molecular mechanism of anagrelide on the inhibition of platelet production using imMKCLs as an ideal model for human megakaryogenesis and platelet formation. Materials and Methods : imMKCLs, established at Center for iPS Cell Research and Application, Kyoto University, Japan, were cultured in Iscove's modified Dulbecco's medium with thrombopoietin (TPO), stem cell factor (SCF), and doxycycline. The differentiation of imMKCLs and platelet generation were induced by doxycycline removal. The generation of mature platelets was observed approximately 7 days after the differentiation was initiated. Both undifferentiated and differentiated imMKCLs were treated with several different concentrations of anagrelide. The cell proliferation and number of generated platelets following anagrelide treatment were analyzed by BrdU cell proliferation assay and flow cytometry, respectively. To explore the molecular mechanism of anagrelide treatment in imMKCLs, we performed mRNA sequencing in imMKCLs treated with or without anagrelide followed by gene ontology (GO) analysis and gene set enrichment analysis (GSEA). The expression of genes related to megakaryogenesis and platelet formation was also analyzed utilizing quantitative real-time PCR. Results : Anagrelide exposure caused morphologically suppressive changes in the differentiation of imMKCLs. Anagrelide treatment also suppressed the mRNA expression of the megakaryocytic surface markers CD41 and CD61 in both undifferentiated (P < 0.01 and P < 0.001, respectively) and differentiated (P < 0.01 and P < 0.001, respectively) settings. The BrdU incorporation rate in differentiated imMKCLs decreased significantly following anagrelide treatment (P < 0.001, anagrelide 0 vs. 1 or 10 µM). The resultant generation of mature platelets (double positive for CD41 and CD42b) was significantly decreased by exposure to anagrelide, as analyzed by flow cytometry (P < 0.001). Regarding the molecular mechanism of anagrelide treatment on imMKCLs, GO analysis following RNA sequencing demonstrated that gene sets related to platelet activation and degranulation were significantly downregulated in both undifferentiated and differentiated conditions. Moreover, GSEA revealed that gene sets related to the cell cycle, such as mitosis and DNA replication, were decreased as well as platelet-specific genes. The mRNA expression levels of genes related to megakaryogenesis and platelet-formation, such as FLI1, TAL1, GATA1, and PF4, were significantly downregulated, especially in differentiated imMKCLs, by anagrelide treatment (P < 0.001, P = 0.013, P < 0.01, and P < 0.01, respectively). Conclusions : We successfully reproduced the platelet-lowering effect of anagrelide by using imMKCLs from human iPS cells that could generate functional platelets in culture. Our RNA sequencing results revealed that anagrelide specifically suppressed megakaryogenesis and platelet formation-related genes. Additional studies including an apoptosis assay and cell cycle analysis of imMKCLs following anagrelide exposure are ongoing to elucidate further molecular mechanisms of anagrelide treatment. Disclosures Takayama: Megakaryon co. Ltd.: Research Funding. Eto:Megakaryon co. Ltd.: Research Funding." @default.
• W2912319965 created "2019-02-21" @default.
• W2912319965 creator A5000196826 @default.
• W2912319965 creator A5004483807 @default.
• W2912319965 creator A5013301436 @default.
• W2912319965 creator A5016085863 @default.
• W2912319965 creator A5018231177 @default.
• W2912319965 creator A5018463402 @default.
• W2912319965 creator A5024180329 @default.
• W2912319965 creator A5026218407 @default.
• W2912319965 creator A5027496527 @default.
• W2912319965 creator A5029593209 @default.
• W2912319965 creator A5030750112 @default.
• W2912319965 creator A5041674771 @default.
• W2912319965 creator A5047821211 @default.
• W2912319965 creator A5048967405 @default.
• W2912319965 creator A5062040392 @default.
• W2912319965 creator A5068249765 @default.
• W2912319965 creator A5079640536 @default.
• W2912319965 creator A5082010384 @default.
• W2912319965 creator A5085289666 @default.
• W2912319965 creator A5086949282 @default.
• W2912319965 creator A5089012786 @default.
• W2912319965 date "2018-11-29" @default.
• W2912319965 modified "2023-10-01" @default.
• W2912319965 title "Anagrelide Inhibits Proliferation and Platelet Generation in Immortalized Megakaryocyte Progenitor Cell Lines Established from Human Induced Pluripotent Stem Cells" @default.
• W2912319965 doi "https://doi.org/10.1182/blood-2018-99-111683" @default.
• W2912319965 hasPublicationYear "2018" @default.
• W2912319965 type Work @default.
• W2912319965 sameAs 2912319965 @default.
• W2912319965 citedByCount "0" @default.
• W2912319965 crossrefType "journal-article" @default.
• W2912319965 hasAuthorship W2912319965A5000196826 @default.
• W2912319965 hasAuthorship W2912319965A5004483807 @default.
• W2912319965 hasAuthorship W2912319965A5013301436 @default.
• W2912319965 hasAuthorship W2912319965A5016085863 @default.
• W2912319965 hasAuthorship W2912319965A5018231177 @default.
• W2912319965 hasAuthorship W2912319965A5018463402 @default.
• W2912319965 hasAuthorship W2912319965A5024180329 @default.
• W2912319965 hasAuthorship W2912319965A5026218407 @default.
• W2912319965 hasAuthorship W2912319965A5027496527 @default.
• W2912319965 hasAuthorship W2912319965A5029593209 @default.
• W2912319965 hasAuthorship W2912319965A5030750112 @default.
• W2912319965 hasAuthorship W2912319965A5041674771 @default.
• W2912319965 hasAuthorship W2912319965A5047821211 @default.
• W2912319965 hasAuthorship W2912319965A5048967405 @default.
• W2912319965 hasAuthorship W2912319965A5062040392 @default.
• W2912319965 hasAuthorship W2912319965A5068249765 @default.
• W2912319965 hasAuthorship W2912319965A5079640536 @default.
• W2912319965 hasAuthorship W2912319965A5082010384 @default.
• W2912319965 hasAuthorship W2912319965A5085289666 @default.
• W2912319965 hasAuthorship W2912319965A5086949282 @default.
• W2912319965 hasAuthorship W2912319965A5089012786 @default.
• W2912319965 hasBestOaLocation W29123199651 @default.
• W2912319965 hasConcept C104317684 @default.
• W2912319965 hasConcept C107459253 @default.
• W2912319965 hasConcept C109159458 @default.
• W2912319965 hasConcept C145103041 @default.
• W2912319965 hasConcept C1491633281 @default.
• W2912319965 hasConcept C201750760 @default.
• W2912319965 hasConcept C203014093 @default.
• W2912319965 hasConcept C2776958478 @default.
• W2912319965 hasConcept C2777863708 @default.
• W2912319965 hasConcept C2779705218 @default.
• W2912319965 hasConcept C2780829020 @default.
• W2912319965 hasConcept C2781057849 @default.
• W2912319965 hasConcept C28328180 @default.
• W2912319965 hasConcept C29537977 @default.
• W2912319965 hasConcept C502942594 @default.
• W2912319965 hasConcept C54355233 @default.
• W2912319965 hasConcept C71924100 @default.
• W2912319965 hasConcept C86803240 @default.
• W2912319965 hasConcept C89560881 @default.
• W2912319965 hasConcept C95444343 @default.
• W2912319965 hasConcept C98274493 @default.
• W2912319965 hasConceptScore W2912319965C104317684 @default.
• W2912319965 hasConceptScore W2912319965C107459253 @default.
• W2912319965 hasConceptScore W2912319965C109159458 @default.
• W2912319965 hasConceptScore W2912319965C145103041 @default.
• W2912319965 hasConceptScore W2912319965C1491633281 @default.
• W2912319965 hasConceptScore W2912319965C201750760 @default.
• W2912319965 hasConceptScore W2912319965C203014093 @default.
• W2912319965 hasConceptScore W2912319965C2776958478 @default.
• W2912319965 hasConceptScore W2912319965C2777863708 @default.
• W2912319965 hasConceptScore W2912319965C2779705218 @default.
• W2912319965 hasConceptScore W2912319965C2780829020 @default.
• W2912319965 hasConceptScore W2912319965C2781057849 @default.
• W2912319965 hasConceptScore W2912319965C28328180 @default.
• W2912319965 hasConceptScore W2912319965C29537977 @default.
• W2912319965 hasConceptScore W2912319965C502942594 @default.
• W2912319965 hasConceptScore W2912319965C54355233 @default.
• W2912319965 hasConceptScore W2912319965C71924100 @default.
• W2912319965 hasConceptScore W2912319965C86803240 @default.
• W2912319965 hasConceptScore W2912319965C89560881 @default.
• W2912319965 hasConceptScore W2912319965C95444343 @default.
• W2912319965 hasConceptScore W2912319965C98274493 @default.
• W2912319965 hasIssue "Supplement 1" @default.
• W2912319965 hasLocation W29123199651 @default.

• next